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SUMOylation has been implicated in cellular stress
adaptation, but its role in regulating liver kinase B1
(LKB1), amajor upstream kinase of the energy sensor
AMP-activated protein kinase (AMPK), is unknown.
Here, we show that energy stress triggers an in-
crease in SUMO1 modification of LKB1, despite a
global reduction in both SUMO1 and SUMO2/3 con-
jugates. During metabolic stress, SUMO1 modifica-
tion of LKB1 lysine 178 is essential in promoting its
interaction with AMPK via a SUMO-interacting motif
(SIM) essential for AMPK activation. The LKB1
K178R SUMO mutant had defective AMPK signaling
and mitochondrial function, inducing death in en-
ergy-deprived cells. These results provide additional
insight into how LKB1-AMPK signaling is regulated
during energy stress, and they highlight the critical
role of SUMOylation in maintaining the cell’s energy
equilibrium.INTRODUCTION
Energy homeostasis in a cell is critical for its survival during
metabolic stress. Liver kinase B1 (LKB1), one of the key reg-
ulators of cellular energy balance, was initially discovered as
a tumor suppressor mutated in patients with Peutz-Jeghers
syndrome (Hemminki et al., 1998). Germline mutations in
LKB1 predispose patients to develop multiple benign and ma-
lignant tumors, including gastrointestinal and lung cancers
(Sanchez-Cespedes, 2007). In 2003, several groups demon-
strated that LKB1 is a major upstream kinase of the energy
sensor AMP-activated protein kinase (AMPK), directly impli-
cating it in the regulation of energy balance in cells (Shackel-
ford and Shaw, 2009). During energy stress, LKB1 phosphor-
ylates AMPK at threonine 172 (T172), resulting in AMPK
activation (Hardie and Alessi, 2013). This leads to the inhibition
of anabolic pathways, such as fatty acid synthesis, and activa-
tion of energy-producing pathways, such as glycolysis. Some
of the proteins targeted include the following: ACC1 (fatty acid734 Cell Reports 12, 734–742, August 4, 2015 ª2015 The Authorssynthesis), ACC2 (fatty acid oxidation), mTORC1 (protein syn-
thesis), and ULK1 (mitophagy) (Shackelford and Shaw, 2009;
Hardie and Alessi, 2013). Therefore, LKB1 is strategically posi-
tioned as an essential kinase in maintaining cellular energy
balance.
A number of studies have described the influence of cova-
lent post-translational modifications in governing LKB1 activ-
ity (Alessi et al., 2006; Lan et al., 2008). However, the role of
SUMOylation in regulating LKB1 function is unknown.
SUMOylation is the reversible covalent attachment of a small
ubiquitin-related modifier (SUMO) protein to a target protein
(Geiss-Friedlander and Melchior, 2007; Okura et al., 1996).
This process has been implicated in important processes
such as transcription, protein stability, and protein subcellular
localization (Yeh, 2009). SUMOylation can (1) inhibit the inter-
action between the target and its interacting partner;
(2) enhance this interaction through the creation of a binding
surface where the target would recognize the partner via a
SUMO-interacting motif (SIM); or (3) change the conformation
of the target, thereby altering its function (Wilkinson and Hen-
ley, 2010). Given the diverse roles SUMOylation plays in the
eukaryotic cell, we hypothesized that, during energy stress,
SUMOylation regulates the LKB1-AMPK interaction and that
this accordingly affects the kinase activity of AMPK.
Our findings here demonstrate that energy stress triggers an
increase in the modification of LKB1 by SUMO1 despite a global
reduction in both SUMO1 and SUMO2/3 conjugates. During
metabolic stress, LKB1 is specifically modified by SUMO1 at
lysine 178 (K178), but not by SUMO2/3, acetylation, or ubiquiti-
nation. This modification is essential in promoting LKB1-AMPK
interaction. On the basis of the crystal structure depicting the
non-covalent recognition of SUMO1 by RanBP2, we identified
a SIM in the N-terminal region of AMPK. Mutation of the hydro-
phobic residues necessary for SUMO1 interaction prevented
LKB1 from recognizing and activating AMPK. Finally, we
observed that cells with the LKB1 K178R SUMO mutant had
defective AMPK signaling and mitochondrial function, inducing
apoptosis in energy-deprived cells. Thus, we propose a model
in which energy stress upregulates the modification of LKB1
by SUMO1, thereby facilitating its interaction with AMPK. This
enhances the rate at which AMPK can respond to the metabolic
needs of the cell.
RESULTS
SUMO1 Modification of LKB1 Is Upregulated during
Energy Stress
To our knowledge, the SUMOylation status of LKB1 has not been
established. We therefore made use of Sentrin/SUMO-specific
protease 1 (SENP1) (Yeh et al., 2000) to first characterize LKB1
SUMOylation. We noted an increase in modification of LKB1
by SUMO1 in HEK293 cells in which endogenous SENP1 was
knocked down by SENP1-specific small interfering RNA (siRNA)
(Figure 1A). To further verify the SUMOylation of LKB1, we over-
expressed either HA-tagged SUMO1 or HA-tagged SUMO2/3
together with LKB1 cDNA in LKB1-null HeLa cells, and we
demonstrated that LKB1 was modified by both SUMO1 mono-
meric and SUMO2/3 polymeric chains (Figures 1B, S1A, and
S1B). In vitro SUMOylation experiments corroborated that
LKB1 is indeed SUMOylated (Figure S1C). These findings estab-
lish that both endogenous and exogenous LKB1 are modified by
SUMOylation.
Since LKB1 is a critical protein involved in maintaining energy
homeostasis in a cell, we investigated whether there were any
LKB1 SUMOylation changes that occur during metabolic stress.
We inducedenergy stress inHEK293 (expressing empty vector or
FLAG SENP1) by subjecting the cells to low-glucose conditions,
low glucose together with glycolysis inhibitor 2-DG, or treatment
with phenformin (a biguanide compound that inhibits complex 1
of the mitochondria). CAMKK inhibitor STO-609 was included in
the treatment regimen since CAMKKb can compensate for
LKB1 by phosphorylating AMPK on the same site (Woods et al.,
2005). Interestingly, immunoprecipitation of LKB1 revealed an in-
crease in SUMO1 modification of LKB1 as the intracellular ATP
levels declined (Figures 1C and S1D). On the other hand, LKB1
conjugation by SUMO2/3 decreased when the cells were treated
with phenformin (Figure S1D). As a control, LKB1 was knocked
down by a specific siRNA in HEK293 cells, and we observed a
marked reduction in the energy stress-induced SUMO1 modifi-
cation of LKB1 (Figure 1D). In addition, we noted that energy
depletion led to a global decrease in both SUMO1- and
SUMO2/3-conjugated proteins (Figures S1D–S1F). This pheno-
type was reversed when MG132, a proteasome inhibitor, was
added to the treatment regimen (Figure S1F). These data imply
that degradation of proteins, in general, is a downstream conse-
quence of metabolic stress, and this may be vital in ensuring that
the cell meets its energy demands.
To broaden the physiological relevance of our observations,
we also looked at the SUMOylation status of LKB1 during stress
in a mouse myoblast cell line, C2C12, which actively depend on
AMPK to maintain energy balance. We noted an increase in
LKB1 SUMO1 modification when C2C12 cells were subjected
to energy stress (Figure S1G). Overall, our data suggest that, dur-
ing stress, the SUMO1 modification of LKB1 might be important
in maintaining the energy homeostasis in a cell.
To prove this hypothesis, we overexpressed empty vector
(pcDNA3) or SENP1 in HEK293 cells and treated the cell cultures
with vehicle (CAMKK inhibitor) alone or with phenformin for 20 hr.
As expected, we detected a decrease in AMPK activation in the
SENP1-overexpressing cells (Figure 1E). Notably, there was a
decrease in expression of both the SUMO-specific proteasesSENP1 and SENP2 upon metabolic stress (Figures 1C and 1E–
1G). The relevance of this observation was confirmed when we
further demonstrated, through in vivo and in vitro systems, that
SENP1 does regulate basal LKB1 catalytic activity (Figure 1H).
Our data suggest that SENP1 may directly or indirectly inhibit
LKB1 autophosphorylation and reduce its catalytic activity.
Therefore, it is plausible to suggest that degradation of SENP1
and SENP2 is important in ensuring maximal SUMOylation-
mediated LKB1 activation, thereby allowing the appropriate
cellular response during energy stress. All things considered,
our data propose that LKB1 SUMOylation is essential in main-
taining the cell’s energy balance.
LKB1 K178 Is Modified by SUMO1 during Energy Stress
The covalent conjugation of a SUMO protein to a target’s lysine
residue is dictated by a consensus motif (JKxe, in whichJ is an
aliphatic branched amino acid and x is any amino acid) (Yeh
et al., 2000). In some cases, this motif is not observed, and a
lysine residue can be modified by SUMO in a non-consensus
mode (Wilkinson and Henley, 2010). To identify the possible
LKB1 lysine residues that may be SUMO1 modified during en-
ergy stress, we used SUMOylation site prediction software
(Ren et al., 2009) that took into consideration the different types
(i.e., through consensus and non-consensus motifs) of SUMO
conjugation. The software generated a number of lysine targets
and we chose the top three candidates with the best cutoff
scores: K96, K122, and K178. We generated LKB1 K96R,
K122R, and K178R mutants and transfected them or their wild-
type counterpart into HeLa cells (LKB1 null) together with HA-
SUMO1. The cells were subjected to energy stress by phenfor-
min for 6 hr, and then LKB1 was immunoprecipitated and the ly-
sates blotted for HA. We observed that, upon metabolic stress,
SUMO1 modification of the LKB1 K178R mutant was markedly
lower than that of wild-type LKB1 (Figure 2A). However,
SUMO1 modification of the LKB1 K96R mutant remained unal-
tered (Figure S2A). The LKB1 K122R mutant was unstable and
thus not tested further (data not shown). Notably, when the cells
were not subjected to energy stress, levels of SUMO1-modified
LKB1 remained the same for both the wild-type and K178R
mutant LKB1 (Figure S2B). Thus, the SUMOylation status of
the K178R mutant only changed upon metabolic stress. These
data suggest that, during energy stress, K178 is a critical
SUMO1 conjugation site. Since lysine residues also can be
modified by SUMO2/3, acetylation, and ubiquitination, we exam-
ined whether these post-translational modifications occurred in
the LKB1 K178R mutant during energy stress. We found that
themodification of K178 by SUMO2/3, acetylation, or ubiquitina-
tion was not altered in these conditions (Figures 2A–2C). These
results led to the conclusion that, during energy stress, conjuga-
tion of K178 with SUMO1 may be important in regulating LKB1
function in maintaining the energy equilibrium in a cell.
Owing to the proximity of lysine 178 to the active site, we had
to ascertain that mutating the lysine to arginine did not alter LKB1
catalytic activity. While the Peutz-Jeghers syndrome LKB1 mu-
tations (Q170P, I177N, N181E, and L182P) impeded the forma-
tion of the LKB1-STRADa-MO25 heterotrimeric complex, which
is important in the allosteric activation of LKB1 (Alessi et al.,
2006), the LKB1 K178R mutant did not (Figure 2D). Thus,Cell Reports 12, 734–742, August 4, 2015 ª2015 The Authors 735
Figure 1. SUMO1 Modification of LKB1 Is Upregulated during Energy Stress
(A) Endogenous SUMO1 modification of LKB1 in HEK293 cells in which SENP1 expression level was knocked down by siRNA. Immunoprecipitates were
subjected to western blot using the indicated antibodies. Messenger RNA levels of SENP1 were measured by quantitative real-time PCR. Data are presented as
the mean ± SD (error bars).
(B) SUMOylation of LKB1 via co-expression of HA-SUMO1 and LKB1 cDNAwith or without FLAG SENP1 in HeLa cells (LKB1 null) is shown. See also Figures S1A
and S1B.
(legend continued on next page)
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mutation of K178 to arginine did not change the ability of LKB1 to
form this active complex. Moreover, the autophosphorylation
status and kinase activity of the LKB1 K178R mutant remained
unaltered (Figures 2E and 2F). This further demonstrates that
LKB1 K178R is not a kinase-dead mutant.
To further evaluate the physiological relevance of the specific
LKB1 K178R mutant in the maintenance of the cell’s energy bal-
ance, we transfected empty vector (pcDNA3), wild-type LKB1, or
LKB1 K178R into LKB1-null HeLa cells and treated the cell cul-
tures with phenformin and STO-609 at the indicated times to
induce metabolic stress. Interestingly, the phosphorylation of
endogenous AMPK at T172 was markedly reduced in cells ex-
pressing empty vector (pBABE) or the LKB1 K178R mutant (Fig-
ures 2G and S2C). Notably, in these cells in which the phosphor-
ylation of AMPK was basally high, the CAMKK inhibitor inhibited
AMPK activation, suggesting that CAMKK is the major upstream
AMPK-activating kinase in LKB1-null settings. Indeed, this phe-
nomenon also was observed in LKB1-null A549 cells (Figure 4A).
We noted that this is a cell-type-specific trait, since AMPK phos-
phorylation increased in HEK293 cells subjected to metabolic
stress (Figures 1C–1G). This observation is consistent with pre-
vious studies demonstrating that activated AMPK can act as
an ally in regulating cancer cell survival by maintaining NADPH
levels (Jeon et al., 2012). Taken together, our findings demon-
strate the importance of the SUMO1 modification of LKB1
K178 in activating AMPK.
SUMOylation Promotes LKB1-AMPK Interaction
Previous studies have demonstrated that proteins can non-
covalently interact with SUMO via their SIM and that this may
promote the interaction between the protein and its substrate
or partner (Kerscher, 2007). Given that SUMOylation is important
in regulating protein-protein interaction, we examined whether
the LKB1 K178R mutant had lower affinity to AMPK than the
wild-type LKB1. We observed that, during energy stress, wild-
type LKB1 bound AMPKmore than the LKB1K178Rmutant (Fig-
ure 3A). Furthermore, overexpression of the deSUMOylating
enzymeSENP1 caused amarked decrease in LKB1-AMPK inter-
action in stable LKB1-expressing A549 cells (Figure 3B) as well
as in HEK293 cells that endogenously expressed wild-type
LKB1 (Figure S3A). To establish that SUMO1 was responsible
for the increase in LKB1-AMPK interaction during energy stress,
we assessed whether SUMO1 interacted with AMPK. We over-
expressed vector control or HA-SUMO1 in A549 cells and(C) HEK293 cells (expressing empty vector or FLAG SENP1) were subjected to e
glycolysis inhibitor 20 mM 2-DG, or treatment with 5 mM phenformin; 10 mg/ml
immunoprecipitated and its SUMO1 conjugation levels were assessed. Whole-
addition, intracellular ATP levels were evaluated in these cells. Data are presente
(D) HEK293 cells expressing either non-targeting or LKB1-specific siRNA were
phenformin for 6 hr. LKB1 was immunoprecipitated and its SUMO1 conjugation
(E) HEK293 cells were transiently transfected with either empty vector (pcDNA3)
alone or with 5 mM phenformin. Whole-cell lysates were subjected to western b
(F) Endogenous SENP1 or SENP2 levels were detected in HEK293 cells treated
(G) HEK293 cells transfected with FLAG SENP1 or SENP2 were treated with vehic
subjected to western blot using the indicated antibodies.
(H) LKB1 was immunoprecipitated from HEK293 cells expressing either vector c
incubated with recombinant human His6 SENP1 catalytic domain. LKB1 autopho
using the indicated antibodies. *IgG bandconducted a co-immunoprecipitation study. As expected,
endogenous AMPK co-precipitated with HA-SUMO1 (Figure 3C)
and also with endogenous SUMO1 in HEK293 cells (Figure S3B).
We then determined whether this interaction was mediated via
a SIM by conducting a competition assay using peptides con-
taining the SUMO E3 ligase PIASy SIM sequence. We observed
that the SIM peptides reduced the affinity of the SUMO1 beads
to the GST-AMPK recombinant protein (Figure 3D). As a control,
we also demonstrated that boiled SUMO1 beads have a lower
affinity to AMPK. This affirmed that AMPK does interact with
SUMO1 via a SIM.
To further confirm this model, we sought to locate a possible
SIM using the consensus motifs predicted by previous studies
(Hecker et al., 2006). Various SIMs have been proposed, but
the common theme in all the paradigms is the presence of a hy-
drophobic core that is often flanked by a cluster of negatively
charged amino acids (Geiss-Friedlander and Melchior, 2007;
Kerscher, 2007). Using the crystal structure depicting the non-
covalent recognition of SUMO1 by RanBP2 through b strand
interactions (taken from Protein Data Bank [PDB]: 3UIP) as a
structural basis, we then searched for potential SIMs in AMPK
(Figure 3E). We identified a conserved region in the N-terminal
region of AMPK that conforms to the specifications of a SIM pro-
posed byMinty et al. (2000; Figure 3F). Biotinylatedwild-type and
mutant AMPK SIM peptides were designed and generated (Fig-
ure 3G). We then performed a competition assay and observed
that the wild-type AMPK SIM peptides competed with GST-
AMPK recombinant protein, thereby decreasing the affinity of
GST-AMPK to SUMO1 (Figure 3G). Finally, the peptides were
conjugated to avidin beads to generate resin for a peptide pull-
down assay. HEK293 cell lysates were incubated with the pep-
tide-bound resin and their affinity to LKB1 was assessed. As
expected, the binding affinity of the mutant AMPK SIM peptides
to endogenous LKB1 was markedly lower than that of the wild-
type SIM peptide (Figure 3H). These results confirmed that the
predicted AMPK SIM was indeed vital in recognizing SUMO1
and may eventually be important in enhancing LKB1-AMPK
interaction.
We further verified this model by mutating both hydrophobic
residues (V93 and I94) to alanines in AMPK cDNA and checked
their binding affinities to SUMO1 and LKB1. V93 and I94 are
mostly solvent exposed, suggesting that their mutation to ala-
nines is unlikely to compromise the 3D fold or stability of the
AMPK domain (Figure 3E). We found that the double SIMnergy stress for 6 hr though low-glucose conditions, low glucose together with
CAMKK inhibitor STO-609 was included in the treatment regimen. LKB1 was
cell lysates were subjected to western blot using the indicated antibodies. In
d as the mean ± SD (error bars).
treated with vehicle (10 mg/ml CAMKK inhibitor STO-609) alone or with 5 mM
was assessed.
or FLAG SENP1 followed by treatment for 20 hr with vehicle (CAMKK inhibitor)
lot using the indicated antibodies.
with vehicle (CAMKK inhibitor) alone or with 5 mM phenformin for 15 hr.
le (CAMKK inhibitor) alone or with 5 mM phenformin for 15 hr. Cell lysates were
ontrol or FLAG SENP1. The precipitates were equally divided and one set was
sphorylation status was assessed. Cell lysates were subjected to western blot
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Figure 2. LKB1 K178 Is Modified by SUMO1 and Is Critical in Activating AMPK
(A–C) Post-translational modification of LKB1 wild-type and K178R mutant by (A) SUMO1 and SUMO2, (B) acetylation, and (C) ubiquitin in HeLa cells during
metabolic stress (2 mM phenformin and 10 mg/ml STO-609) is shown. See also Figure S2B.
(D) Wild-type LKB1, LKB1 K178R mutant, and the various Peutz-Jeghers syndrome LKB1 mutants (Q170P, I177N, N181E, and L182P) were transfected and
immunoprecipitated from HeLa cells, and their interactions with STRADa and MO25 were assessed.
(E and F) LKB1 was immunoprecipitated from HeLa cells transiently expressing empty vector (pcDNA3), wild-type LKB1, or LKB1 K178R mutant. (E) An in vitro
kinase assay using GST-AMPKA1 recombinant protein was performed. (F) Autophosphorylation of LKB1 and the LKB1 K178R mutant was analyzed.
(G) A549 cells (LKB1 null) stably expressing empty vector (pcDNA3), wild-type LKB1, or LKB1mutant K178R were treated with 2mM phenformin and/or 10 mg/ml
STO-609 as indicated. Cell lysates were subjected to western blot using the indicated antibodies. See also Figure S2C.AMPK mutant (VI93-94AA) had a lower affinity to both SUMO1
and LKB1 in AMPKa/ mouse embryo fibroblast (MEF) cells
than wild-type AMPK (Figures 3I and 3J). To prove that this
finding is physiologically relevant, we then checked whether738 Cell Reports 12, 734–742, August 4, 2015 ª2015 The Authorsthis SIM mutant affected AMPK phosphorylation. We noted a
consistent decrease in phosphorylation of AMPK when the cells
transfectedwith the AMPKSIMmutant were subjected to energy
depletion (Figures 3J and S3D). The single SIM AMPK mutant
Figure 3. SUMOylation Promotes LKB1-AMPK Interaction
(A) In vivo assay in HeLa cells of binding between AMPK and LKB1 wild-type or K178R mutant after 6 hr of metabolic stress is shown.
(B) Stably LKB1-expressing A549 cells were transiently transfectedwith either empty vector (pcDNA3) or FLAGSENP1 followed by treatment for 20 hr with vehicle
(CAMKK inhibitor) alone or with 2 mM phenformin. LKB1 was immunoprecipitated from lysates and their interaction with AMPK was assessed. See also
Figure S3A.
(C) Co-immunoprecipitation assay of endogenous AMPK and HA-SUMO1 in A549 cells is shown.
(D) In vitro SUMO1 pull-down assay of GST-AMPKA1 recombinant protein in the absence or presence of PIASy SIM peptides is shown.
(E) The AMPK domain is shown (green; PDB: 4CFH). Highlighted are the following: inhibitory staurosporin (white carbons), V93 (gray), I94 (orange), phosphor-
ylated T172 (yellow carbons), and the activation loop (orange). (Top right) Zoom onto I94 shows that I94 is mostly solvent exposed, suggesting that its mutation to
alanine is unlikely to compromise the 3D fold or stability of the AMPK domain. (Bottom right) The non-covalent recognition of SUMO1 (blue) by RanBP2 (green,
only the interacting part is shown) through b strand interactions (PDB: 3UIP) was used as a structural basis for the search for potential SIMs in AMPK. The di-
hydrophobic motif figuring a valine and isoleucine are shown. The AMPK N-terminal b sheet offers a surface similar to a potential SIM (top right).
(F) A schematic shows a conserved region in the N-terminal region of AMPK that conforms to the specifications of a previously proposed SIM (Minty et al., 2000).
(G) In vitro SUMO1 pull-down assay of GST-AMPKA1 recombinant protein in the presence of wild-type or mutant AMPK SIM peptides is shown.
(H) Peptide pull-down assay of biotinylated wild-type or mutant AMPK SIM peptides conjugated to avidin beads in HEK293 cell lysates is shown.
(I and J) In vivo assay in AMPKa/MEF cells of binding between AMPK or AMPK SIMmutants and (I) SUMO1 and (J) LKB1 after 6 hr of metabolic stress. Whole-
cell lysates were subjected to western blot using the indicated antibodies.(I94A), which we found was important in the activation of AMPK
during stress (Figure S3D), decreased the SUMO1-AMPK inter-
action (Figure S3C), but not with LKB1 (Figure 3J). This indicates
that, while I94 is the key hydrophobic residue in the SIM, both
V93 and I94 are important in regulating LKB1-AMPK interaction
and activation during stress. Together, these data support the
hypothesis that LKB1 is modified by SUMO1 at K178 during en-ergy stress, thereby enabling the recognition of AMPK through
its SIM, leading to AMPK activation.
LKB1 K178 SUMOylation Is Essential in the AMPK
Signaling Pathway
We then examinedwhether AMPK signaling is defective in LKB1-
null cells expressing the LKB1 K178R mutant, resulting inCell Reports 12, 734–742, August 4, 2015 ª2015 The Authors 739
Figure 4. LKB1K178 SUMOylation Is Essen-
tial in the AMPK Signaling Pathway
(A) A549 cells stably expressing empty vector
(pBABE), wild-type LKB1, LKB1 mutant (K178R),
or kinase-dead LKB1 (K78I) were treated with
vehicle control (DMEM) or with 10 mg/ml CAMKK
inhibitor STO-609 alone or with 2 mM phenformin
for 48 hr to induce metabolic stress. Cell lysates
were subjected to western blot using the indicated
antibodies.
(B) Cells stably expressing the indicated plasmids
stained with annexinV and 7AAD after a 48-hr
treatment with vehicle (10 mg/ml STO-609) alone or
with 2 mM phenformin were subjected to fluores-
cence-activated cell sorting (FACS) analysis.
(C) FACS analysis of the indicated cells stained
with MitoTracker Red is shown.
(D) Oxygen consumption rate (OCR) of cells from
(C) is shown. Error bars represent mean ± SEM.
See also Figure S4B.
(E) Proposed model for the SUMO1-mediated
regulation of LKB1-AMPK interaction during en-
ergy stress is shown.impaired mitochondrial function, and the induction of apoptosis
(Shackelford et al., 2013). LKB1-null A549 cells stably trans-
fected with empty vector (pBABE), wild-type LKB1, LKB1
K178R, or kinase-dead LKB1 (K78I) were treated with vehicle
control (DMEM) or with CAMKK inhibitor STO-609 alone or
with phenformin for 48 hr to induce metabolic stress. Immuno-
blotting for phosphorylation of AMPK downstream substrates,
ACC1 at Ser79, ULK1 at Ser555, and Raptor at Ser792, showed
that the cells expressing empty vector, kinase-dead mutant, and
the LKB1 K178R mutant were defective in AMPK signaling (Fig-
ure 4A). Furthermore, through the measurement of intracellular
ATP levels, we confirmed that A549 cells stably expressing
wild-type LKB1 recovered and maintained the energy balance
better than cells expressing empty vector or K178R LKB1
SUMO mutant (Figure S4A).
Apoptosis, as demonstrated by cleaved PARP and caspase-3
(Figure 4A) and annexinV and 7AAD staining (Figure 4B), was
increased in the phenformin-treated cells expressing empty
vector (pBABE), kinase-dead LKB1, or LKB1 K178R mutant,
but not wild-type LKB1. Remarkably, the basal levels of acti-
vated AMPK were relatively high in these LKB1-null A549 cells.
Inhibition of CAMKK led to a decrease in AMPK activation, but740 Cell Reports 12, 734–742, August 4, 2015 ª2015 The Authorsdid not induce apoptosis (Figure 4B).
This is consistent with findings that
illustrate the potency of phenformin in
inducing death in LKB1-null cells (Shack-
elford et al., 2013). Since the phosphory-
lation of ULK1 is required for mitophagy
(Egan et al., 2011), we checked the mito-
chondrial content of these cells using
MitoTracker Red staining. Consistent
with our previous biochemical results,
LKB1-null cells reconstituted with the
wild-type LKB1 had less retention of the
mitochondrial fluorescent dye than cellsexpressing the empty vector, kinase-dead LKB1, or LKB1
K178R mutant (Figure 4C). These findings illustrate that LKB1
K178 SUMOylation is essential in the clearance of defective
mitochondria, consequently enabling the efficient production
of energy during metabolic stress (Melser et al., 2013). To
assess the mitochondrial health of these different cells, we
also checked the oxygen consumption rates as a measure of
mitochondrial respiration. As expected, A549-vector, A549-
LKB1 dead-kinase, and A549-LKB1 K178R mutant cells had
lower basal oxygen consumption rates than A549 cells trans-
fected with wild-type LKB1 (Figures 4D and S4B). Taken
together, these data confirm that SUMO1 modification of
LKB1 K178 is indeed important in maintaining cellular energy
balance during metabolic stress.
DISCUSSION
SUMOylation has been implicated in diverse biological pro-
cesses, including protein stability (Yeh, 2009), DNA damage
response (Dou et al., 2010), and immune system development
(Van Nguyen et al., 2012). However, insights into its fundamental
role in regulating metabolism are still in the nascent stages
(Wilkinson and Henley, 2010). Our study elaborates on how
SUMOylation influences this cellular process and defines the
SUMOylation changes that occur to maintain homeostasis in
conditions of metabolic stress.
LKB1 is a major upstream kinase of AMPK, which is a vital
player in sensing energy stress and eliciting the correct adaptive
responses to ensure cell survival. Anabolic processes are in-
hibited, while processes that generate energy are activated (Har-
die and Alessi, 2013). AMPK also is involved in regulating
mitophagy (Egan et al., 2011). This process facilitates the effec-
tive elimination of defective mitochondria, consequently
enabling the cell to maintain full mitochondrial fitness and effi-
cient respiration (Melser et al., 2013). Accumulation of malfunc-
tioning mitochondria leads to an increase in levels of reactive ox-
ygen species, thereby initiating apoptosis (Murphy, 2009). This
therefore highlights the significance of LKB1-AMPK activation
in calibrating the cell’s energy balance and regulating cell
survival.
Here we demonstrate that LKB1 is increasingly conjugated by
SUMO1 during metabolic stress. The importance of SUMO1
modification of LKB1 was validated when we saw that SENP1
hampers the ability of LKB1 to bind, phosphorylate, and activate
AMPK during energy stress. We further illustrated that lysine 178
is the site that is important for SUMO1 conjugation (and not
SUMO2/3, acetylation, or ubiquitylation) during metabolic
stress. In normal conditions, there is no difference in SUMO1
conjugation of either wild-type LKB1 or the LKB1 K178Rmutant.
However, during metabolic stress, SUMO1 conjugation mark-
edly increases in the wild-type LKB1, but not in the K178mutant.
These results suggest that LKB1 is modified by SUMO1 at lysine
residues other than K178 under normal conditions. In addition,
we note that the SUMO1 conjugation of LKB1 at K178 leads to
increased binding and activation of AMPK.
A number of studies have characterized the importance of
SIMs in dictating protein interactions, thereby influencing their
downstream functions (Kerscher, 2007). Our study provides an
additional example that illustrates the importance of a SIM in aid-
ing the recognition and activation of AMPK by LKB1 during
stress. Using the crystal structure depicting the non-covalent
recognition of SUMO1 by RanBP2 as a structural basis, we iden-
tified a SIM in the N-terminal region of AMPK.Mutation of the hy-
drophobic residues necessary for SUMO1 interaction prevents
LKB1 from recognizing and activating AMPK. Interestingly, in
the AMPK crystal structure produced with a truncation in the
carbohydrate-binding module (also called glycogen-binding
domain) of the b subunit (PDB: 4CFH), the kinase N-lobe surface
containing the SIM is completely solvent exposed and the kinase
domain is in its fully activated conformation (Xiao et al., 2011).
Conversely, in the AMPK structure including the full-length car-
bohydrate-binding module, the C-interacting helix (residues
161–170) of the b subunit (PDB: 4CFE) binds close to the SIM,
contacting the catalytically important aC helix of the kinase
domain. In this structure, the aC helix is in a catalytically inactive
conformation, supposedly promoted by the C-interacting helix
(Xiao et al., 2013). The C-interacting helix has above-average b
factors in the crystal structure, suggesting increased mobility
and hence a loose interaction. We therefore speculate that bind-
ing of SUMO1 to the SIM also promotes AMPK activation by dis-placing the C-interacting helix, and, hence, may allosterically
activate AMPK by rearranging the aC helix, as seen in many
other kinases (Endicott et al., 2012). LKB1 also can phosphory-
late and activate 12 other AMPK-related kinases (Alessi et al.,
2006). Examining whether SIMs are involved in facilitating these
interactions is beyond the scope of this study, but will be further
investigated.
Taken together, our results support a model in which energy
stress triggers SUMO1 modification of LKB1 at K178, leading
to activation of its downstream target and energy sensor,
AMPK (Figure 4E).
EXPERIMENTAL PROCEDURES
Antibodies and siRNAs
Antibodies used for immunoblotting, including LKB1 (D60C5; 3047), phospho-
AMPK Thr172 (2531), total AMPKa 1/2 (2532), phospho-Raptor Ser792 (2083),
total Raptor (2280), phospho-ULK1 (S555; 5869), total ULK1 (8054), and
SUMO1 (4930), were obtained from Cell Signaling Technology. Actin (sc-
47778) and AMPKa1 (ab32047) antibodies were obtained from Santa Cruz
Biotechnology and Abcam, respectively. Nontargeting siRNA (ON-TARGET-
plus 2, catalog number D-001810-02-20) and SENP1 siRNA (ON-TARGETplus
SMARTpool Human SENP1, catalog number L-006357-00-0010) were pur-
chased from Dharmacon.
Cell Culture and Transfections
Non-small-cell lung carcinoma A549 cells, cervical cancer HeLa cells, HEK293
cells, Phoenix cells, and AMPKa/MEFs were maintained in DMEM (Thermo
Fisher Scientific) containing 10% fetal bovine serum (Thermo Fisher Scientific),
penicillin, and streptomycin. The cells were incubated at 37C at 5% CO2
levels. The AMPKa/ MEF cell line was a gift from Dr. Hui-Kuan Lin. Myc-
AMPK and catalytic mutant Myc-AMPK (D157A) were gifts from Dr. David
Carling, and pBabe empty vector was a gift from Dr. Hui-Kuan Lin. pBabe-
FLAG-LKB1 (8592), pBabe-FLAG-LKB1-KD (8593), and pcDNA3-FLAG-
LKB1 (8590) were obtained from Addgene.
Non-targeting siRNA, SENP1 siRNA, and plasmid DNA (HA-SUMO1, HA-
SUMO2,Myc-AMPK, catalyticmutantMyc-AMPK [D157A], pBabe empty vec-
tor, pBabe-FLAG-LKB1, pBabe-FLAG-LKB1-KD, and pcDNA3-FLAG-LKB1)
were transfected into cells using Lipofectamine 2000 (Invitrogen) per the man-
ufacturer’s instructions. Six hours after transfection, the medium containing
the Lipofectamine reagent was changed and replaced with serum-containing
medium; the cells then were allowed to recover overnight before further
experimentation.
Additional experimental procedures are described in the Supplemental
Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and four figures and can be found with this article online at http://dx.doi.org/
10.1016/j.celrep.2015.07.002.
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